PI3Kδ/γ and BCL2 Inhibition Synergize in Models of Richter Syndrome

Article navigation

Research Watch| June 01 2021

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2021

American Association for Cancer Research.

Cancer Discov (2021) 11 (6): OF11.

Abstract

The PI3Kδ/γ inhibitor duvelisib and the BCL2 inhibitor venetoclax synergized in vivo and ex vivo

2021

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.